Evidence map›Paper›PMID 28179471›Full record

Trial reportNeurology2017

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

Peter A LeWitt, Jia Li, Mei Lu, Lining Guo, Peggy Auinger, Parkinson Study Group–DATATOP Investigators

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 154 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Parkinson disease is a fatty acidopathy.Nature reviews. Neurology · 2025
    Review
  11. Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  12. Article
  13. Article
  14. Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Peter A LeWittFrom the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY. plewitt1@hfhs.org.
Jia LiFrom the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY.
Mei LuFrom the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY.
Lining GuoFrom the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY.
Peggy AuingerFrom the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY.
Parkinson Study Group–DATATOP Investigators
Wayne State University · USMetabolon (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether a Parkinson disease (PD)-specific biochemical signature might be found in the total body metabolic milieu or in the CSF compartment, especially since this disorder has systemic manifestations beyond the progressive loss of dopaminergic nigrostriatal neurons.

methodsOur goal was to discover biomarkers of PD progression. Using ultra-high-performance liquid chromatography linked to gas chromatography and tandem mass spectrometry, we measured concentrations of small-molecule (≤1.5 kDa) constituents of plasma and CSF from 49 unmedicated, mildly affected patients with PD (mean age 61.4 years; mean duration of PD 11.4 months). Specimens were collected twice (baseline and final) at intervals up to 24 months. During this time, mean Unified Parkinson's Disease Rating Scale (UPDRS) parts 2 + 3 scores increased 47% (from 28.8 to 42.2). Measured compounds underwent unbiased univariate and multivariate analyses, including fitting data into multiple linear regression with variable selection using least absolute shrinkage and selection operator (LASSO).

resultsOf 575 identified plasma and 383 CSF biochemicals, LASSO led to selection of 15 baseline plasma constituents with high positive correlation (0.87,

conclusionsMetabolomic profiling of plasma yielded strong prediction of PD progression and offered biomarkers that may provide new insights into PD pathogenesis.

Indexed as

MetabolomeAdultAgedBiomarkersChromatography, High Pressure LiquidDisease ProgressionFemaleGas Chromatography-Mass SpectrometryHumansLinear ModelsMaleMiddle AgedParkinson DiseaseRetrospective StudiesSeverity of Illness IndexBiomarkers

Identifiers

PMID28179471
PMCPMC5331866
OpenAlexW2587271278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.